KDR and liver cancer: Molecular-based targeted therapies are also increasingly becoming systemic treatments for liver cancer, including Sorafenib (RAF/MEK/ERK signaling pathway inhibitor, VEGFR and PDGFR inhibitor), Lenvatinib (VEGFR-1, VEGFR-2, VEGFR-3, FGFR1, PDGFR, cKit and Ret inhibitor), Bevacizumab (VEGF inhibitor) and other monoclonal antibodies.